slide deck (pdf) - CME Outfitters
slide deck (pdf) - CME Outfitters slide deck (pdf) - CME Outfitters
Phosphodiesterase type 5 Inhibitors for use in BPH-LUTS Medication Dose Indication Tadalafil 2.5 mg per day BPH Tadalafil 5.0 mg per day BPH and ED Common side effects: headache, back pain, dizziness, flushing and dyspepsia. Contraindicated in patients who use nitrates, potassium channel openers, or non-selective 2nd generation Abs. Cardiac status must be assessed for patient risk before taking this medications. 1.Roehrborn CG, et al. J Urol. 2008;180(4):1228-1234. PMID: 18722631. 2.Oelke M, et al. Eur Urol. 2013;64(1):118-140. PMID: 23541338. 3.Nehra A, et al. Mayo Clin Proc. 2012;87(8):766-778. PMID: 22862865.
Rosenberg MT, et al. Publication Pending The Next STEP: Step 3
- Page 3 and 4: Accreditation This program has been
- Page 5 and 6: Learning Objectives ! Explain the s
- Page 7 and 8: Matt T. Rosenberg, MD Disclosures S
- Page 9 and 10: Disclosures ! Faculty of this CE ac
- Page 11 and 12: Get Social with Us CMEOutfitters.co
- Page 13 and 14: Georgia Association of Physician As
- Page 15 and 16: Matt T. Rosenberg, MD Disclosures S
- Page 17 and 18: In what percentage of your patients
- Page 19 and 20: Function of the Prostate Normal Fun
- Page 21 and 22: Benign Prostatic Hyperplasia ! A co
- Page 23 and 24: Predominant Symptoms ! The enlarged
- Page 25 and 26: Definition of OAB International Con
- Page 27 and 28: How to differentiate the etiology o
- Page 29 and 30: Common Comorbidities in BPH-LUTS Co
- Page 31 and 32: Audience Response Question Fact: ED
- Page 33 and 34: BPH-LUTS and ED Common Pathophysiol
- Page 35 and 36: What to Keep in Mind in the Evaluat
- Page 37 and 38: The Evaluation of LUTS: History, Ph
- Page 39 and 40: Medications Can Cause or Exacerbate
- Page 41 and 42: Laboratory Tests ! Urinalysis ! Inf
- Page 43 and 44: Audience Response Question The most
- Page 45 and 46: The Purpose of the Voiding Diary !
- Page 47 and 48: Rosenberg MT, et al. Publication Pe
- Page 49 and 50: STEP 1: Informed Surveillance If th
- Page 51 and 52: Clinical Management Step2a: Alpha B
- Page 53: Clinical Management Step2b: Phospho
- Page 57 and 58: Antimuscarinics - Immediate Release
- Page 59 and 60: ! Dry Mouth ! Constipation ! Headac
- Page 61 and 62: Beta 3 Agonists Drug Mirabegron Dos
- Page 63 and 64: Clinical Management Step3b: Adding
- Page 65 and 66: 5 Alpha Reductase Inhibitors (5ARI)
- Page 67 and 68: Rosenberg MT, et al. Publication Pe
- Page 69 and 70: Clinical Connections: Summary ! Tre
Rosenberg MT, et al. Publication Pending<br />
The Next STEP:<br />
Step 3
Change language